
    
      This will be an open-label study to evaluate the efficacy and safety of ingenol mebutate gel,
      0.015% used in topical therapy of actinic keratosis on the chest. Subjects that present with
      4 or more actinic keratosis in one continuous 100cm2 area of the chest and meet all
      inclusion/exclusion criteria will be enrolled into this study.

      Treatment with the investigational product (IP) will be applied for three continuous days.
      The investigator will guide application of the IP in-office at Day 0 and the subject will be
      instructed to self-administer the IP at Days 1 and 2. Follow-up visits will be scheduled at
      Days 1, 3, 10, 17, 24 and 59.

      Prior to treatment and at each visit, the investigator will assess the subject's treatment
      area for lesion counts and at follow up visits 4, 5, 6 and 7 evaluation of clearance.
      Pre-treatment photography will also be collected at baseline and at each follow up visit.
    
  